The 2024 AIM-HI Women’s Venture Competition Announced 4 Semi-Finalists!

Exciting News! The AIM-HI Accelerator Fund is thrilled to announce 4 Semi-Finalists competing in our Women’s Venture Competition this year, selected from a pool of 58 applications submitted by women-led, early-stage oncology companies from 10 different countries!

Congratulations to these outstanding women entrepreneurs and their companies:

• AOA Dx | Oriana Papin-Zoghbi | CEO & Co-Founder
• ARMA Bio | Paraskevi Giannakakou, Ph.D. | CSO
• HDAX Therapeutics | Nabanita Nawar, Ph.D. | CEO & Co-Founder
• Utter Therapeutics | Deborah Charych, Ph.D. | CEO

The winning early-stage oncology company of 2024 Women’s Venture Competition will be eligible to receive investment from AIM-HI and co-investors, subject to due diligence, which will serve as early seed money for proof of concept and proof of value on the path to clinical trials and, eventually, to new effective therapeutics that could save patients’ lives.

We would like to extend our heartful thanks to the selection and judging committee members for their tremendous support of AIM-HI and invaluable contributions to empower women scientist-entrepreneurs in oncology.

Trying to promote the involvement of women in cancer biotech as entrepreneurs is a great cause, and we want to say thank you to all of our dear supporters for helping advance that cause.